Article Text

PDF
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90)
  1. Kirsty Stewart1,
  2. Matthew Walters2,
  3. Jesse Dawson2
  1. 1NHS Education for Scotland, Glasgow, UK
  2. 2Institute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
  1. Correspondence to Dr Jesse Dawson, College of Medicine, Veterinary and Life Sciences, Institute of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow G11 6NT, UK; jesse.dawson{at}glasgow.ac.uk

Abstract

The National Institute for Health and Clinical Excellence has recently published an update of technology appraisal guidance 90, first published in 2005, which evaluated the use of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. This article considers the update in detail and discusses the implications for clinical practice.

  • Antiplatelet treatment
  • platelets

Statistics from Altmetric.com

Footnotes

  • Competing interests Dr Dawson has previously received speaker honoraria for lectures on anti-platelet therapy from Sanofi-Aventis and Bristol Myers Squibb.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.